Subject:
- Active Sustance: Valoctocogene roxaparvovec
- Name: Roctavian®
- Therapeutic area: Hemophilia A
- Pharmaceutical company: BioMarin International Ltd.
Time table:
- Start: 15.09.2022
- Final decision by G-BA: 16.03.2023
Final decision:
- Hint for a non-quantifiable additional benefit (orphan drug)